Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [916]

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Language and understanding: The complexity of insight in cancer care

Dr Tianna Martin - Beaumont Hospital, Dublin, Ireland

Language and understanding: The complexity of insight in cancer care ( Dr Tianna Martin - Beaumont Hospital, Dublin, Ireland )

Understanding patient experience in Europe: The first Global Lung Cancer...

Vanessa Beattie - Lung Cancer Nursing UK, Solihull, England

Understanding patient experience in Europe: The first Global Lung Cancer Coalition Patient Experience Survey ( Vanessa Beattie - Lung Cancer Nursing UK, Solihull, England )

CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients...

Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK

CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients with limited-stage SCLC ( Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK )

First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and...

Dr Martina Lorenzi - University of Padua, Padua, Italy

First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the real-world ( Dr Martina Lorenzi - University of Padua, Padua, Italy )

AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4 cycles chemo in aNSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as...

Dr Patrick M. Forde - Johns Hopkins University, Baltimore, USA

CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neoadjuvant treatment for resectable NSCLC ( Dr Patrick M. Forde - Johns Hopkins University, Baltimore, USA )

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than...

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

First-line pembrolizumab plus chemotherapy for patients with advanced squamous...

Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General...

First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407 ( Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Canada )

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II...

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

Cemiplimab plus ipilimumab for advanced NSCLC

Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea

Cemiplimab plus ipilimumab for advanced NSCLC ( Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea )

More from ecancer